Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

liraglutide

- PMLiVE

Q&A: Niels Lund

PME interviews Novo Nordisk's Vice President, Health Advocacy

- PMLiVE

Sanofi joins Lilly in insulin price cut, but lawmakers have lost patience

Insulin price nearly tripled between 2002 and 2013

- PMLiVE

Sanofi exits R&D pact with Alnylam on rare disease

Exit also frees up $700m equity investment

- PMLiVE

Trump takes aim at Obamacare with repeal move

Aims to dismantle the programme

- PMLiVE

Success for AZ, setback for Sanofi in type 1 diabetes

Forxiga approved as add-on to insulin

- PMLiVE

Novo uses voucher for speedy answer on oral semaglutide

Oral version of Ozempic could be diabetes market leader

- PMLiVE

J&J’s Spravato breaks depression drought at FDA

The esketamine nasal spray is the first new-mechanism antidepressant to be licensed in decades

- PMLiVE

Trump’s Brexit trade plan is bad for NHS, say campaigners

People’s Vote claims US wants to end NHS’ current regime of controlling drug costs

- PMLiVE

Novartis back in the spotlight over Trump/Cohen links

Cohen said the fee intended to get him to work as a lobbyist

- PMLiVE

CMS proposes coverage scheme for CAR-T therapies

Proposal says it would improve access to CAR-Ts

- PMLiVE

Sanofi extends growth spurt thanks to Genzyme, Dupixent

US approval of Cablivi adds to good news

- PMLiVE

Sanofi gets US okay for $270,000 blood disorder drug Cablivi

First in a new class of single-domain antibody fragments drugs

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links